Inhaled glucocorticosteroids are currently the most effective anti-inflammatory controller medications for treating persistent asthma. The efficacies of glucocorticoids include reducing asthma symptoms, reducing exacerbation frequency, improving quality of life, improving lung function, decreasing airway hyperresponsiveness, controlling airway inflammation, and reducing mortality. However, the treatment response to glucocorticosteroids in asthmatics varies, and certain subtypes of asthma, such as refractory asthma, respond poorly to high-dose inhaled glucocorticoid and systemic steroids. The medical costs of treating refractory asthmatics represent about 50% of the total healthcare cost for asthma. A thorough understanding of the mechanisms of glucocorticoid action, patient responses to glucocorticoids, and steroid resistance observed in refractory asthmatics is necessary for the targeted development of therapeutic drugs. This review discusses the characteristics of severe refractory asthmatics and the mechanisms of steroid response and resistance in asthma treatment.
INTRODUCTION
Asthma is a chronic inf lammatory airway disease involving episodic breathlessness and wheezing with airway hyperresponsiveness to environmental stimuli [1] [2] [3] . Airway inf lammation in asthmatic patients is characterized by degranulated mast cells, infiltrating eosinophils, and an increased number of activated helper T-lymphocytes [1] [2] [3] . In asthma, many different inflammatory mediators such as lipid mediators, inf lammatory peptides, chemokines, cytokines, and growth factors are increased [1] [2] [3] . The structural cells of the airways, including epithelial cells, airway smooth muscle cells, endothelial cells, and fibroblasts, also are a major source of inflammatory mediators in asthma [3] . Airway remodeling in both large and small airways has been documented in all degrees of asthma severity [4] .
Structural changes in airway remodeling include loss of epithelial integrity, thickening of the basement membrane, subepithelial fibrosis, goblet cell and submucosal gland enlargement, increased smooth muscle mass, decreased cartilage integrity, and increased airway vascularity [4] [5] [6] [7] . Inhaled glucocorticoids are currently the most effective anti-inflammatory controller medications for the treatment of persistent asthma [1] [2] [3] in Korea [1, 2] and are recommended by the Global Initiative for Asthma (GINA) guidelines [3] .
The prevalence of asthma is about 5-10% of the general population. Of these, approximately 5-10% are severe refractory asthmatics who respond poorly to asthmatic drugs, including high-dose inhaled steroids [5] [6] [7] [8] [9] [10] [11] [12] . Severe refractory asthmatics have persistent symptoms, frequent symptom exacerbation, and severe airway obstruction even when taking high-dose inhaled steroids.
The subtypes of severe asthma [13] [14] [15] [16] [17] [18] include fatal or near fatal asthma, steroid-dependent asthma, steroidresistant asthma, difficult-to-control asthma, poorly controlled asthma, brittle asthma, and irreversible asthma. Patients who do not reach an acceptable level of control at step 4 of the GINA guidelines (reliever medication plus two or more controllers) are defined as having difficult-to-control asthma [3] . The American Thoracic Society [16] has defined refractory asthma (RA) as followings. RA was defined by one or both major criteria and one minor criteria as followings: 1) major criteria: treatment with continuous or near continuous (> 50% of year) oral corticosteroids (CS), requirement for treatment with high-dose inhaled CS; 2) minor criteria: a) requirement for daily treatment with a controller medication in addition to inhaled CS, e.g., long-acting β-agonist, theophylline, or leukotriene antagonist, b) asthma symptoms requiring short-acting β-agonist use on a daily or near daily basis, c) persistent airway obstruction (forced expiratory volume in one second [FEV1] < 80% predicted, diurnal peak expiratory flow [PEF] variability > 20%), d) one or more urgent care visits for asthma per year, e) three or more oral steroid "bursts" per year, f) prompt deterioration with ≤ 25% reduction in oral or inhaled corticosteroid dose, g) near fatal asthma event in the past.
This review discusses the characteristics of severe asthma, including RA, and the mechanisms of steroid response and steroid resistance in the treatment of asthma.
CHARACTERISTIC OF SEVERE ASTHMA
Subtypes of difficult-to-control asthma ( Nocturnal asthma has an early morning dip and double dip. Premenstrual asthma is unstable asthma that occurs 2-5 days before menses. Steroid-resistant asthma is diagnosed in those rare patients who take highdose steroids (10-to 14-day course of prednisone ≥ 20 mg twice daily), but experience less than 15% improvement from baseline FEV1. Steroid-dependent asthma is defined as asthma that can be controlled only with high doses of oral steroids; it may be part of a continuum with steroid-resistant asthma at the other extreme.
Acute and severe asthma are diagnosed in patients with acute or subacute exacerbation with dyspnea, wheezing, chest tightness, and decreased lung function.
Status asthmaticus leads to acute respiratory failure and can cause death (fatal asthma). Severe asthma is classified according to cell type, e.g., eosinophils and neutrophils [18] [19] [20] [21] . Eosinophilic asthma observed on bronchoalveolar lavage and mucosal biopsy causes decreased lung function and occasional near-fatal events.
Clinical characteristics of severe asthma
Severe asthma, including RA, represents 10-20% of asthma cases and is associated with more drug medications and more hospital visits and admissions than mild to moderate asthma. Mortality occurs in 3-35% of severe asthma cases, and the medical cost to treat severe asthma is more than 50% of the total medical cost for treating asthmatic patients [22] .
Risk factors for severe asthma are genetic and environmental, including many kinds of aeroallergens, beta-blockers, and anti-inflammatory drugs. Gastroesophageal reflux disease can affect asthma symptoms 
Pathophysiological characteristics of severe asthma
Severe asthma can be classified based on four different pathological aspects. fibrosis [29] . Reticular basement thickening is related to asthma severity [30, 31] . 4) Severe asthma can also be classified according to changes in both large and small airways [32] .
MECHANISMS OF STEROID Steroid responses
Glucocorticoids, the mainstay of asthma management, bind to glucocorticoid receptors (GRs) in the cytosol, thereby activating the translocation of GRs to the nucleus. In the nucleus, GR binds to specific gene regulatory elements to induce the expression of genes involved in regulating airway inflammation (Table 2 ) [33] .
In a study of steroid responses in patients with moderate to severe asthma, the relationship between responsiveness and the FEV1% predicted and blood and sputum eosinophil levels prior to glucocorticoid inhala- tion were investigated [28] . In this study, 86 adult asth- 
Steroid resistance
Those rare patients with steroid-resistant asthma exhibit less than 15% improvement in baseline FEV1 after a 10-to 14-day course of high-dose steroids (prednisone ≥ 20 mg twice daily). Proposed mechanisms leading to steroid resistance in asthma include intrinsic defects in neutrophils and mast cells, airway structural abnormalities, increases in inflammatory mediators related to steroid receptors, decreases in steroid receptor number and/or binding capacity, increases in GR-β, transcriptional factor repression, existence of steroid-resistant neutrophils, imbalance between acetylation and deacetylation, and airway remodeling [6, 34, 35] .
Factors that may contribute to steroid resistance are listed in Table 3 [35, 36] . These include a decreased number and/or genetic variation of GR; abnormal GR 
